Skip to main content
SpringerLink
Log in

Molecular aspects of the imipramine ‘receptor’

  • Published:
Experientia Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Abbot, W. M., Briley, M. S., Langer, S. Z., and Sette, M., Sodium shift of the inhibition of (3H)-imipramine binding of 5-HT and 5-HT-uptake blockers but not by tricyclic antidepressants. Br. J. Pharmac.76 (1982) 295P.

    Google Scholar 

  2. Ahtee, L., Briley, M., Raisman, R., Lebrec, D., and Langer, S. Z., Reduced uptake of serotonin but unchanged3H-imipramine binding in the platelets from cirrhotic patients. Life Sci.29 (1981) 2323–2329.

    Article  CAS  PubMed  Google Scholar 

  3. Arora, R. C., and Meltzer, H. Y., Serotonin uptake by blood platelets of schizophrenic patients. Psychiat. Res.6 (1982) 327–333.

    Article  CAS  Google Scholar 

  4. Arora, R. C., Tong, C., Jackman, H. L., Stoff, D., and Meltzer, H. Y., Serotonin uptake and imipramine binding in blood platelets and brain of Fawn-Hooded and Sprague-Dawley rats. Life Sci.33 (1983) 437–442.

    Article  CAS  PubMed  Google Scholar 

  5. Asarch, K. B., Shih, J. C., and Kulscar, A., Decreased3H-imipramine binding in depressed males and females. Commun. Psychopharmac.4 (1980) 425–432.

    CAS  Google Scholar 

  6. Barbaccia, M. L., Brunello, N., Chuang, D. M., and Costa, E., On the mode of action of imipramine: Relationship between serotonergic axon terminal function and down-regulation of β-adrenergic receptors. Neuropharmacology22 (1983) 373–383.

    Article  CAS  PubMed  Google Scholar 

  7. Bayer, S. M., and McCoy, E. E., A comparison of the serotonin and ATP content in platelets from subjects with Down's syndrome. Biochem. Med.9 (1974) 255–232.

    Article  Google Scholar 

  8. Berrettini, W. H., Nurnberger, J. I., Post, R. M., and Gershon, E. S., Platelet3H-imipramine binding in euthymic bipolar patients. Psychiat. Res.7 (1982) 215–219.

    Article  CAS  Google Scholar 

  9. Bhargara, K. P., Raina, N., Mishra, N., Shanker, K., and Vrat, S., Uptake of serotonin by human platelets and its relevance to CNS involvement in hypertension. Life Sci.25 (1979) 195–200.

    Article  Google Scholar 

  10. Bogdanski, D. F., Tissari, B., and Brodie, B. B., Role of sodium, potassium, ouabain and reserpine in uptake, storage and metabolism of biogenic amines in synaptosomes. Life Sci.7 (1968) 419–428.

    Article  CAS  PubMed  Google Scholar 

  11. Bouillin, D. J., and O'Brien, R. A., Abnormalities of 5-hydroxytryptamine uptake and binding by blood platelets from children with Down's syndrome. J. Physiol.212 (1971) 287–297.

    Article  Google Scholar 

  12. Briley, M. S., Raisman, R., Sechter, D., Zarifian, E., and Langer, S. Z., [3H]-Imipramine binding in human platelets: A new biochemical parameter in depression. Neuropharmacology19 (1980) 1209–1210.

    Article  CAS  PubMed  Google Scholar 

  13. Briley, M. S., Langer, S. Z., Raisman, R., Sechter, D., and Zarifian, D., Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients. Science209 (1980) 303–305.

    Article  CAS  PubMed  Google Scholar 

  14. Briley, M., and Langer, S. Z., Sodium dependency of [3H] imipramine binding to rat cerebral cortex. Eur. J. Pharmac.72 (1981) 377–380.

    Article  CAS  Google Scholar 

  15. Briley, M., Langer, S. Z., Raisman, R., and Sette, M., Localization of [3H]-imipramine binding sites on serotonin nerve terminals. Br. J. Pharmac.74 (1981) 217P.

    Google Scholar 

  16. Briley, M. S., Langer, S. Z., and Sette, M., Allosteric interaction between the3H-imipramine binding site and the serotonin uptake mechanism. Br. J. Pharmac.74 (1982) 817–818P.

    Google Scholar 

  17. Briley, M. S., Raisman, R., Arbilla, S., Casadamont, M., and Langer, S. Z., Concomitant decrease in [3H] imipramine binding in cat brain and platelets after chronic treatment with imipramine. Eur. J. Pharmac.81 (1982) 809–814.

    Article  Google Scholar 

  18. Brunello, N., Chuang, D. M., and Costa, E., Different synaptic location of mianserin and imipramine binding sites. Science25 (1982) 1112–1115.

    Article  Google Scholar 

  19. Burkard, W. P., Specific binding sites in rat brain for a new and potent inhibitor of 5-hydroxytryptamine uptake: Ro 112465. Eur. J. Pharmac.61 (1980) 409–410.

    Article  CAS  Google Scholar 

  20. Campbell, I. C., Blood platelets and psychiatry. Br. J. Psychiat.138 (1980) 78–80.

    Article  Google Scholar 

  21. Carlsson, A., Fuxe, K., and Ungerstept, U., The effect of imipramine on central 5-hydroxytryptamine neurons. J. Pharm. Pharmac.20 (1968) 150–151.

    Article  CAS  Google Scholar 

  22. Caron, M. G., and Lefkowitz, R. J., Solubilization and characterisation of the β-adrenergic receptor binding sites of frog erythyrocytes. J. biol. Chem.251 (1976) 2374–2384.

    Article  CAS  PubMed  Google Scholar 

  23. Coppen, A., Swade, C., and Wood, K., Platelet 5-hydroxytryptamine accumulation in depressive illness. Clinica chim. Acta87 (1978) 165–168.

    Article  CAS  Google Scholar 

  24. Coppen, A., Swade, C., Wood, K., and Carroll, J. D., Platelet 5-hydroxytryptamine and migraine. Lancet 8148 (1979) 914.

    Article  Google Scholar 

  25. Cuatrecasas, P., Isolation of the insulin receptor of liver and fatcell membranes. Proc. natl Acad. Sci.69 (1972) 318–322.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. DaPrada, M., Pieri, L., Keller, H. H., Pieri, M., and Bonnetti, E. P., Effects of 5,6-dihydroxytryptamine and 5,7-dihydroxytryptamine on rat central nervous system after intraventricular or intracerebral application and on blood platelets and on blood platelets in vivo. Ann. N. Y. Acad. Sci.305 (1978) 595–620.

    Article  CAS  Google Scholar 

  27. Davis, A., Conformational changes in [3H] imipramine binding sites; possible role of disulphide bridges. J. Neurochem.41 (1983) S. 106D. Proceedings of International Society Neurochemistry, July 1983 meeting, Vancouver.

  28. Davis, A., Kinetic properties of [3H] 2-nitroimipramine binding to human platelets. Eur. J. Pharmac.96 (1983) 105–110.

    Article  CAS  Google Scholar 

  29. Davis, A., Determination of the hydrodynamic properties of detergent solubilized proteins. Receptor Biochemistry and Methodology, in: Molecular and Chemical Characterization of Membrane Proteins, pp. 161–178. Eds J. C. Venter and L. Harrison. Liss, Inc. New York 1984.

    Google Scholar 

  30. Davis, A., The use of [3H] Ro 11-2465 in the solubilization, partial purification and reconstitution of platelet imipramine binding sites. Soc. Neurosci. Abstr.9 (1983) 334.

    Google Scholar 

  31. Davis, A., Reconstitution of [3H] Ro 11-2465 binding sites solubilised from human platelets. Eur. J. Pharmac. (1983) submitted.

  32. Davis, A., Madras, B., and Seeman, P., Solubilization of neuroleptic/dopamine receptors of human brain striatum. Eur. J. Pharmac.70 (1981) 321–329.

    Article  CAS  Google Scholar 

  33. Davis, A., Madras, B. K., and Seeman, P., Solubilized receptor for3H-dopamine (D3 binding sites) from dog brains. Biochem. Pharmac.31 (1982) 1183–1187.

    Article  CAS  Google Scholar 

  34. Davis, A., Morris, J. M., and Tang, S. W., Solubilization and assay of [3H]-imipramine binding sites from human platelets. Eur. J. Pharmac.86 (1983) 353–359.

    Article  CAS  Google Scholar 

  35. Davis, A., Morris, J. M., and Tang, S. W., Temperature-sensitive conformational changes in membrane bound and solubilized [3H] imipramine binding sites. Eur. J. Pharmac.88 (1983) 407–410.

    Article  CAS  Google Scholar 

  36. Davis, A., Dumbrille-Ross, A., and Tang, S. W., Differentiation between platelet and cortical [3H] imipramine binding sites. Br. J. Pharmac.64 (1983) 664P.

    Google Scholar 

  37. Dumbrille-Ross, A., and Tang, S. W., Absence of high-affinity [3H] imipramine binding in platelets and cerebral cortex of Fawnhooded rats. Eur. J. Pharmac.72 (1981) 137–138.

    Article  CAS  Google Scholar 

  38. Dumbrille-Ross, A., and Tang, S. W., Binding to a subpopulation of3H-imipramine sites by3H-Ro 11-2465, a possible irreversible ligand. Soc. Neurosci. Abstr.8 (1982) 20.

    Google Scholar 

  39. Dumbrille-Ross, A., and Tang, S. W., Binding to a subpopulation of3H-imipramine binding sites by3H-Ro 11-2465, a possible irreversible ligand. Molec. Pharmac.23 (1983) 607–613.

    CAS  Google Scholar 

  40. Dumbrille-Ross, A., Tang, S. W., and Coscina, D. V., Differential binding of3H-imipramine and3H-mianserin in rat cerebral cortex. Life Sci.29 (1981) 2049–2058.

    Article  CAS  PubMed  Google Scholar 

  41. Dumbrille-Ross, A., Morris, J. M., Davis, A., and Tang, S. W., Temperature-sensitive reversible loss of [3H]-imipramine binding sites: Evidence suggesting different conformational states. Eur. J. Pharmac.91 (1983) 383–389.

    Article  CAS  Google Scholar 

  42. Enna, S. J. and Snyder, S. H., Properties of γ-aminobutyric acid (GABA) receptor binding in rat brain synaptic membrane fractions. Brain Res.100 (1975) 81–97.

    Article  CAS  PubMed  Google Scholar 

  43. Ferry, D. R., and Glossmann, H., Evidence for multiple receptor sites within the putative calcium channel. Naunyn-Schmiedebergs Arch. Pharmac.321 (1982) 80–83.

    Article  CAS  Google Scholar 

  44. Freedman, S. B., Poat, J. A., and Woodruff, G. N., Influence of sodium and sulphydryl groups on [3H] sulpiride binding sites in rat striatal membranes. J. Neurochem.38 (1982) 1459–1465.

    Article  CAS  PubMed  Google Scholar 

  45. Furth, A. J., Removing unbound detergent from hydrophobic proteins. Analyt. Biochem.109 (1980) 207–215.

    Article  CAS  PubMed  Google Scholar 

  46. Gay, C., Langer, S. Z., Loo, H., Raisman, R., Sechter, D., and Zarifian, E., (3H)-Imipramine binding in platelets: A state-dependent or independent biological marker in depression? Br. J. Pharmac.78 (1983) 57P.

    Google Scholar 

  47. Glossman, H., Ferry, D. R., Lubecke, F., Mewes, R., and Hoffman, F., Calcium channels: Direct identification with radioligand binding studies. Trends Pharmac. Stud.3 (1982) 431–437.

    Article  Google Scholar 

  48. Goodlet, I., Mireyless, S. E., and Sugrue, M. F., Effects of mianserin, a new antidepressant, on thein vitro andin vivo uptake of monoamine. Br. J. Pharmac.61 (1977) 307–313.

    Article  CAS  Google Scholar 

  49. Gorissen, H., and Laduron, P. M., Solubilization of high-affinity dopamine receptors. Nature279 (1979) 72–79.

    Article  CAS  PubMed  Google Scholar 

  50. Grabowsky, K. L., McCabe, R. T., and Wamsley, J. K., Localization of [3H]-imipramine binding sites in rat brain by light microscopic autoradiography. Life Sci.32 (1983) 2355–2361.

    Article  CAS  PubMed  Google Scholar 

  51. Haefely, W., Schaffner, R., Burkard, W. P., DaPrada, M., Keller, H. H., and Richards, J. G., Ro 11-2465, a potent and selective inhibitor of 5-hydroxytryptamine. 11th Collegium International Neuropsychopharmacology Congress, Vienna 1978, p. 95.

  52. Hall, H., Ross, R., Ogren, S. O., and Gawell, L., Binding of a specific 5-HT uptake inhibitor,3H-norzimelidine to rat brain homogenates. Eur. J. Pharmac.80 (1982) 281–282.

    Article  CAS  Google Scholar 

  53. Hebdon, G. M., Levine, H., Sahyoun, N. E., Schmitges, C. J., and Cuatrecasas, P., Specific phospholipids are required to reconstitute adenylate cyclase solubilised from rat brain. Proc. natl Acad. Sci.78 (1981) 120–123.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Helenius, A., and Simon, K., Solubilization of membranes by detergents. Biochim. biophys. Acta415 (1975) 29–79.

    Article  CAS  PubMed  Google Scholar 

  55. Hjelmeland, L. M., A nondenaturing zwitterionic detergent for membrane biochemistry: Design and synthesis. Proc. natl Acad. Sci.77 (1980) 6368–6370.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Hokin, L. E., Reconstitution of ‘carriers’ in artificial membranes. J. Membr. Biol.60 (1981) 77–93.

    Article  CAS  PubMed  Google Scholar 

  57. Im, W. B., Ling, K. Y., and Faust, R. G., Partial purification of the Na+-dependent D-glucose transport system from renal brush border membranes. J. Membr. Biol.65 (1982) 131–137.

    Article  CAS  PubMed  Google Scholar 

  58. Kaplan, R. D., and Mann, J. J., Altered platelet serotonin uptake kinetics in schizophrenia and depression. Life Sci.31 (1982) 583–588.

    Article  CAS  PubMed  Google Scholar 

  59. Kinnier, W. J., Chuang, D.-M., and Costa, E., Down-regulation of dihydroalprenolol and imipramine binding sites in brain of rats repeatedly treated with imipramine. Eur. J. Pharmac.67 (1980) 289–294.

    Article  CAS  Google Scholar 

  60. Kinnier, W. J., Chuang, D.-M., Gwynn, G., and Costa, E., Characteristics and regulation of high affinity [3H] imipramine of high affinity [3H] imipramine binding to rat hippocampal membranes. Neuropharmacology20 (1981) 411–419.

    Article  CAS  PubMed  Google Scholar 

  61. Kistler, J., Stroud, R. M., Klymkowsky, M. W., Lalancette, R. A., and Fairclough, R. H., Structure and function of an acetylcholine receptor. Biophys. J.37 (1982) 371–383.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Langer, S. Z., and Briley, M., High-affinity3H-imipramine binding: a new biological tool for studies in depression. Trends Neurosci. (1981) 28–31.

  63. Langer, S. Z., Raisman, R., and Briley, M. S., Stereoselective inhibition of3H-imipramine binding by anti-depressant drugs and their derivatives. Eur. J. Pharmac.64 (1980) 89–90.

    Article  CAS  Google Scholar 

  64. Langer, S. Z., Briley, M. S., Raisman, R., Henry, J.-F., and Morselli, P. L., Specific3H-imipramine binding in human platelets. Naunyn-Schmiedebergs Arch. Pharmac.313 (1980) 189–194.

    Article  CAS  Google Scholar 

  65. Langer, S. Z., Moret, C., Raisman, R., Dubocovich, M. I., and Briley, M., High-affinity [3H] imipramine binding in rat hypothalamus: Association with uptake of serotonin but not of norepinephrine. Science210 (1980) 1133–1135.

    Article  CAS  PubMed  Google Scholar 

  66. Langer, S. Z., Javoy-Agid, F., Raisman, R., Briley, M., and Agid, Y., Distribution of specific high affinity binding sites for [3H] imipramine in human brain. J. Neurochem.37 (1981) 267–271.

    Article  CAS  PubMed  Google Scholar 

  67. LeFur, G., and Uzan, A., Effects of 4-(3-indolyl-alkyl) piperidine derivatives on uptake and release of noradrenaline, dopamine and 5-hydroxytryptamine in the rat brain synaptosomes, rat heart and human blood platelets. Biochem. Pharmac.26 (1977) 497–503.

    Article  CAS  Google Scholar 

  68. Lenehan, T., Omer, L. M. O., and Darragh, A., Effect of Ro 11-2465, a new psychotropic agent, on the uptake of serotonin by human platelets: in vitro determination of IC50. Archs int. Pharmacodyn.249 (1981) 147–152.

    CAS  Google Scholar 

  69. Lew, J. Y., Fong, J. C., and Goldstein, M., Solubilization of the neuroleptic binding receptor from rat striatum. Eur. J. Pharmac.72 (1981) 403–405.

    Article  CAS  Google Scholar 

  70. Lilly, L., Eddy, B., Fraser, C. M., Schafer, J., and Venter, J. C., Preparative isoelectric focusing in receptor purification, in: Receptor Biochemistry and Methodology, vol. 2. Eds J. C. Venter and L. C. Harrison, Alan R. Liss Inc., New York 1983, in press.

    Google Scholar 

  71. Lingjaerde, O., Platelet uptake and storage of serotonin, in: Serotonin in Health and Disease, vol. 4, pp. 139–199. Spectrum Publications, New York 1977.

    Google Scholar 

  72. Lingjaerde, O., Inhibitory effect of clomipramine and related drugs on serotonin uptake in platelets: More complicated than previously thought. Psychopharmacology61 (1979) 245–249.

    Article  CAS  PubMed  Google Scholar 

  73. Lingjaerde, O., The biochemistry of depression. Acta psych. scand. suppl. 302 (1983) 36–51.

    Article  Google Scholar 

  74. Long, R. F., and Lessin, A. W., Inhibition of 5-hydroxytryptamine uptake by platelets in vitro and in vivo. Biochem. J.82 (1962) 5P.

    Google Scholar 

  75. Lott, I. T., Chase, T. N., and Murphy, D. L., Down's syndrome: Transport, storage and metabolism of serotonin blood platelets. Pediatr. Res.6 (1972) 730–735.

    Article  CAS  PubMed  Google Scholar 

  76. Madras, B. K., Davis, A., and Seeman, P., Comparison of soluble dopamine D2 receptors from three species. Eur. J. Pharmac.78 (1982) 431–438.

    Article  CAS  Google Scholar 

  77. Marangos, P. J., Campbell, I. C., Suhmechel, D. E., Murphy, D. L., and Goodwin, R. K., Blood platelets contain a neuron-specific enolase. J. Neurochem.34 (1980) 1254–1258.

    Article  CAS  PubMed  Google Scholar 

  78. Martini, C., and Lucacchini, A., Inactivation of benzodiazepine binding sites by N-ethylmalemide. J. Neurochem.38 (1982) 1768–1770.

    Article  CAS  PubMed  Google Scholar 

  79. McCoy, E. E., and Bayer, S. M., Decreased serotonin uptake and ATP'ase activity in platelets from Down's syndrome patients. Clin. Res.21 (1973) 304–310.

    Google Scholar 

  80. McLean, D. R., and Nihei, T., Uptake of dopamine and 5-hydroxytryptamine by platelets from patients with Huntington's chorea. Lancet1 (1977) 249–250.

    Article  CAS  PubMed  Google Scholar 

  81. Mellerup, E. T., Plenge, P., and Rosenberg, R.,3H-Imipramine binding sites in platelets from psychiatric patients. Psychiat. Res.7 (1982) 221–227.

    Article  CAS  Google Scholar 

  82. Mocchetti, O., Brunello, N., and Racagni, G., Ontogenetic study of [3H] imipramine binding sites and serotonin uptake system: indication of possible interdependence. Eur. J. Pharmac.83 (1982) 151–152.

    Article  CAS  Google Scholar 

  83. Modai, I., Rotman, A., Munitz, H., Tjano, S., and Wijsenbeck, H., Serotonin uptake by blood platelets of acute schizophrenic patients. Psychopharmacology64 (1979) 193–195.

    Article  CAS  PubMed  Google Scholar 

  84. Murrey, T. F., DeBarrows, B. R., Prieur, D. J., and Meyers, K. M., [3H]-Imipramine binding sites in Fawn-Hooded rats. Neuropharmacology22 (1983) 781–784.

    Article  Google Scholar 

  85. Nayler, W. G., Calcium antagonism: A new approach. Clin. exp. Pharm. Physiol., suppl.6 (1982) 3–13.

    Google Scholar 

  86. Palkovits, M., Raisman, R., Briley, M., and Langer, S. Z., Regional distribution of [3H] imipramine binding in rat brain. Brain Res.210 (1981) 493–498.

    Article  CAS  PubMed  Google Scholar 

  87. Pasternak, G. W., Wilson, H. A., and Snyder, S. H., Differential effects of protein-modifying reagents on receptor binding of opiate agonists and antagonists. Molec. Pharmac.11 (1975) 340–351.

    CAS  Google Scholar 

  88. Paul, S. M., Rehavi, M., Rice, K. C., Ittah, Y., and Skolnick, P., Does high affinity [3H] imipramine binding label serotonin uptake sites in brain and platelets. Life Sci.28 (1981) 2753–2760.

    Article  CAS  PubMed  Google Scholar 

  89. Paul, S. M., Rehavi, M., Skolnick, P., Ballenger, J. C., and Goodwin, F. K., Depressed patients have decreased binding of [3H] imipramine to the platelet serotonin transporter. Archs gen. Psychiat.38 (1981) 1315–1317.

    Article  CAS  Google Scholar 

  90. Pearse, A. G. E., Common cytochemical and structural characteristics of cells producing polypeptide hormones (the APUD series) and their relevance to thyroid andultimobronchial C cells and calcitonia. Proc. R. Soc. Lond., biol. Sci.170 (1968) 71–80.

    Article  CAS  Google Scholar 

  91. Pearse, A. G. E., The diffuse neuroendocrine system and the common peptides, in: Molecular Endocrinology pp. 309–323. Eds MacIntyre and Szelke. Elsevier, New York and Amsterdam 1977.

    Google Scholar 

  92. Pearse, A. G. E., The endocrine division of the nervous system: a concept and its verification, in: Molecular Endocrinology, pp. 4–17. Eds McIntyre and Szelke. Elsevier, New York and Amsterdam 1979.

    Google Scholar 

  93. Plenge, P., and Mellerup, E. T.,3H-Imipramine high-affinity binding sites in rat brain. Effects of imipramine and lithium. Psychopharmacology77 (1982) 94–97.

    Article  CAS  PubMed  Google Scholar 

  94. Popot, J.-L., Cartaud, J., and Changeux, J.-P., Reconstitution of a functional acetylcholine receptor. Incorporation into artificial lipid vesicles and pharmacology of the agonist-controlled permeability changes. Eur. J. Biochem.118 (1981) 203–214.

    Article  CAS  PubMed  Google Scholar 

  95. Prina, R., Dolfini, E., Mennini, T., Palermo, A., and Libretti, A., Reduced serotonin uptake by spontaneously hypertensive rat platelets. Life Sci.29 (1981) 2375–2379.

    Article  CAS  PubMed  Google Scholar 

  96. Propert, D. N., Tait, B. D., and Davies, B., HLA antigens and affective illness. Tissue Antigens18 (1981) 335–340.

    Article  CAS  PubMed  Google Scholar 

  97. Racker, E., and Kandrach, A., Partial resolution of the enzymes catalysing oxidative phosphorylation. XXIX. Reconstitution of the third segment of oxidative phosphorylation. J. biol. Chem.248 (1973) 5841–5847.

    Article  CAS  PubMed  Google Scholar 

  98. Raisman, R., Briley, M. S., and Langer, S. Z., High-affinity3H-imipramine binding in rat cerebral cortex. Eur. J. Pharmac.54 (1979) 307–308.

    Article  CAS  Google Scholar 

  99. Raisman, R., Briley, M. S., and Langer, S. Z., Specific tricyclic antidepressant binding sites in rat brain characterized by high-affinity3H-imipramine binding. Eur. J. Pharmac.61 (1980) 373–380.

    Article  CAS  Google Scholar 

  100. Raisman, R., Briley, M. S., Bouchami, F., Sechter, D., Zarifian, E., and Langer, S. Z.3H-Imipramine binding and serotonin uptake in platelets from untreated depressed patients and control volunteers. Psychopharmacology77 (1982) 332–335.

    Article  CAS  PubMed  Google Scholar 

  101. Razin, S., Reconstitution of biological membranes. Biochim. biophys. Acta265 (1972) 241–296.

    Article  CAS  PubMed  Google Scholar 

  102. Rehavi, M., Ittah, Y., Rice, K. C., Skolnick, P., Goodwin, F. K., and Paul, S. M., 2-Nitroimipramine: A selective irreversible inhibitor of [3H] serotonin uptake and [3H] imipramine binding in platelets. Biochem. biophys. Res. Commun.99 (1981) 954–959.

    Article  CAS  PubMed  Google Scholar 

  103. Rehavi, M., Ittah, Y., Skolnick, P., Rice, K. C., and Paul, S. M., Nitroimipramines-Synthesis and pharmacological effects of potent long-acting inhibitors of [3H] serotonin uptake and [3H] imipramine binding. Naunyn-Schmiedebergs Arch. Pharmac.320 (1982) 45–49.

    Article  CAS  Google Scholar 

  104. Rehavi, M., Skolnick, P., and Paul, S. M., Solubilization and partial purification of the high affinity [3H] imipramine binding site from human platelets. Febs Letts150 (1982) 514–518.

    Article  CAS  Google Scholar 

  105. Rehavi, M., Tracer, H., Rice, K., Skolnick, P., and Paul, S. M., [3H] 2-Nitroimipramine: A selective ‘slowly-dissociating’ probe of the imipramine binding site (serotonin transporter) in platelets and brain. Life Sci.32 (1983) 645–653.

    Article  CAS  PubMed  Google Scholar 

  106. Reith, M. E. A., Sershen, H., Allen, D., and Lajtha, A., Similarities between central binding sites for cocaine and imipramine. Soc. Neurosci. Abstr.8 (1982) 464.

    Google Scholar 

  107. Reith, M. E. A., Sershen, H., Allen, D. L., and Lajtha, A., A portion of [3H] cocaine binding in brain is associated with serotonergic neurons. Molec. Pharmac.23 (1983) 600–606.

    CAS  Google Scholar 

  108. Rotman, A., Modai, I., Munitz, H., and Wijsenbeck, H., Active uptake of serotonin by blood platelets of schizophrenic patients. Febs Letts101 (1979) 134.

    Article  CAS  Google Scholar 

  109. Rotman, A., Munitz, H., Modai, I., Tjano, S., and Wijsenbeck, H., A comparative uptake study of serotonin, dopamine, and norepinephrine by platelets of acute schizophrenic patients. Psychiat. Res.3 (1980) 239–246.

    Article  CAS  Google Scholar 

  110. Rudnick, G., Active transport of 5-hydroxytryptamine by plasma membrane vesicles isolated from human blood platelets. J. biol. Chem.252 (1977) 2170–2174.

    Article  CAS  PubMed  Google Scholar 

  111. Rudnick, G., and Nelson, P. J., Reconstitution of 5-hydroxytryptamine transport from cholate-disrupted platelet plasma membrane vesicles. Biochemistry17 (1978) 5300–5303.

    Article  CAS  PubMed  Google Scholar 

  112. Ruegg, U. T., Hiller, J. M., and Simon, E. J., Solubilization of an opiate receptor fromBufo marinus. Eur. J. Pharmac.64 (1980) 367–368.

    Article  CAS  Google Scholar 

  113. Seeman, P., Ulpian, C., and Wells, J., Dopamine receptor parameters (detected by3H-spiperone) depend on tissue concentration. Soc. Neurosci. Abstr.8 (1982) 718.

    Google Scholar 

  114. Sette, M., Raisman, R., Briley, M., and Langer, S. Z., Locaization of tricyclic antidepressant bindings sites on serotonin nerve terminals. J. Neurochem.37 (1981) 40–42.

    Article  CAS  PubMed  Google Scholar 

  115. Sette, M., Briley, M. S., and Langer, S. Z., Complex inhibition of [3H] imipramine bindings by serotonin and noncyclic serotonin uptake blockers. J. Neurochem.40 (1983) 622–628.

    Article  CAS  PubMed  Google Scholar 

  116. Simonds, W. F., Koski, G., Streaty, R. A., Hjelmeland, L. M., and Klee, W. A., Solubilization of active opiate receptor. Proc. natl Acad. Sci.77 (1980) 4623–4627.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Sneddon, J. M., Sodium-dependent accumulation of 5-hydroxytryptamine by rat blood platelets. Br. J. Pharmac.37 (1969) 680–688.

    Article  CAS  Google Scholar 

  118. Sneddon, J. M., Blood platelets as a model for monoamine-containing neurons. Prog. Neurobiol.1 (1973) 153–198.

    Article  Google Scholar 

  119. Stacey, R. D., Uptake of 5-hydroxytryptamine by platelets. Br. J. Pharmac.16 (1961) 284–295.

    CAS  Google Scholar 

  120. Stadel, J. M., and Lefkowitz, R. J., Multiple reactive sulfhydryl groups modulate the function of adenylate cyclase coupled betaadrenergic receptors. Molec. Pharmac.16 (1979) 709–718.

    CAS  Google Scholar 

  121. Stahl, S. M., The human platelet: A diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. Archs gen. Psychiat.34 (1977) 509–516.

    Article  CAS  Google Scholar 

  122. Stahl, S. M., Ciaranello, R. D., and Berger, P. A., Platelet serotonin in schizophrenia and depression: a review, in: Serotonin in Biological Psychiatry, Advances in Biochem. Psychopharmac, vol. 34. Eds. B. T. Ho, J. C. Schoolar and E. Usdin. Raven Press, New York 1982.

    Google Scholar 

  123. Stahl, S. M., Woo, D. J., Mefford, I. N., Berger, P. A., and Ciaranello, R. D., Hyperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders. Am. J. Psychiat.140 (1983) 26–30.

    Article  CAS  PubMed  Google Scholar 

  124. Strauss, W. L., Ghai, G., Fraser, C. M., and Venter, J. C., Detergent solubilization of mammalian cardiac and hepatic β-adrenergic receptors. Archs Biochem. Biophys.196 (1979) 566–573.

    Article  CAS  Google Scholar 

  125. Suen, E. T., Stefanini, E., and Clement-Cormier, Y. C., Evidence for essential thiol groups and disulfide bonds in agonist and antagonist binding to the dopamine receptor. Biochim. biophys. Res. Commun.96 (1980) 953–960.

    Article  CAS  Google Scholar 

  126. Suranyi-Cadotte, B. E., Wood, P. L., Vasavan Nair, N. P., and Schwartz, G., Normalization of platelet [3H] imipramine binding in depressed patients during remission. Eur. J. Pharmac.85 (1982) 357–358.

    Article  CAS  Google Scholar 

  127. Suranyi-Cadotte, B. E., Wood, P. L., Schwartz, G., and Vasavan Nair, N. P., Altered platelet3H-imipramine binding in schizoaffective and depressive disorders. Biol. Psychiat.18 (1983) 923–927.

    CAS  PubMed  Google Scholar 

  128. Talvenheimo, J., Nelson, P. J., and Rudnick, G., Mechanism of imipramine inhibition of platelet 5-hydroxytryptamine transport. J. biol. Chem.254 (1979) 4631–4635.

    Article  CAS  PubMed  Google Scholar 

  129. Talvenheimo, J., and Rudnick, G., Solubilization of the platelet plasma membrane serotonin transporter in an active form. J. biol. Chem.255 (1980) 8606–8611.

    Article  CAS  PubMed  Google Scholar 

  130. Todrick, A., and Tait, C., The inhibition of human platelet 5-hydroxytryptamine uptake by tricyclic antidepressive drugs. The relation between structure and potency. J. Pharm. Pharmac.21 (1969) 751–762.

    Article  CAS  Google Scholar 

  131. Toyo-Oka, T., Shimizu, T., and Masaki, T., Inhibition of proteolytic activity of calcium-activated protease by leupeptin and antipain. Biochem. biophys. Res. Commun.82 (1978) 484–491.

    Article  CAS  PubMed  Google Scholar 

  132. Trukenmiller, M. E., Angel, I., Paul, S. M., and Neale, J. H., Antibodies against blood platelets influence 5-HT uptake and imipramine binding in synaptosomes. Soc. Neurosci. Abstr.9 (1983) 568.

    Google Scholar 

  133. Tukianen, E., Tuomisto, J., Westermarck, T., and Kupianen, H., Nature of lowered 5-hydroxytryptamine uptake by blood platelets of patients with Down's syndrome. Acta pharmac. Toxic.47 (1980) 365–370.

    Article  Google Scholar 

  134. Tuomisto, J., A new modification for studying 5-HT uptake by blood platelets: a re-evaluation of tricyclic antidepressants as uptake inhibitors. J. Pharm. Pharmac.26 (1974) 92–100.

    Article  CAS  Google Scholar 

  135. Tuomisto, J., and Tukianen, E., Decreased uptake of 5-hydroxytryptamine in blood platelets from depressed patients. Nature262 (1976) 596–598.

    Article  CAS  PubMed  Google Scholar 

  136. Tuomisto, J., Tukianen, E., and Ahlfors, V. G., Decreased uptake of 5-hydroxytryptamine in blood platelets from patients with endogenous depression. Psychopharmacology65 (1979) 141–147.

    Article  CAS  PubMed  Google Scholar 

  137. Vauquelin, G., Bottari, S., and Strosberg, A. D., Inactivation of β-adrenergic receptors by N-ethylmaleimide: Permissive role of β-adrenergic agents in relation to adenylate cyclase activation. Molec. Pharmac.17 (1980) 163–171.

    CAS  Google Scholar 

  138. Weiland, G. A., Minneman, K. P., and Molinoff, P. B., Fundamental differences between the molecular interactions of agonists and antagonists with the β-adrenergic receptor. Nature281 (1979) 114–117.

    Article  CAS  PubMed  Google Scholar 

  139. Weiland, G. A., Minneman, K. P., and Molinoff, P. B., Thermodynamics of agonist and antagonist interactions with mammalian β-adrenergic receptors. Molec. Pharmac.18 (1980) 341–347.

    CAS  Google Scholar 

  140. Weiland, G. A., and Molinoff, P. B., Quantitative analysis of drug-receptor interactions: 1. Determination of kinetic and equilibrium properties. Life Sci.19 (1981) 313–330.

    Article  Google Scholar 

  141. Weitkamp, L. R., Stancer, H. C., Persad, E., Flood, C., and Guttormsen, G., Depressive disorders and HLA: A gene on chromosome 5 that can affect behaviour. New Engl. J. Med.305 (1981) 1301–1306.

    Article  CAS  PubMed  Google Scholar 

  142. Wennogle, P., Beer, B., and Meyerson, L. R., Human platelet imipramine recognition sites: Biochemical and pharmacological characterization. Pharmac. Biochem. Behav.15 (1981) 975–982.

    Article  CAS  Google Scholar 

  143. Wennogle, L. P., and Meyerson, L. R., Serotonin modulates the dissociation of [3H] imipramine from human platelet recognition sites. Eur. J. Pharmac.86 (1983) 303–307.

    Article  Google Scholar 

  144. Wennogle, L. P., Ashton, R. A., and Meyerson, L. R., Photoaffinity labelling of the imipramine binding site in human platelet membranes with [3H] 2-nitroimipramine. Soc. Neurosci. Abstr.9 (1983) 229.

    Google Scholar 

  145. Wielosz, M., Salmona, M., deGaetano, G., and Garratini, S., Uptake of14C-5-hydroxytryptamine by human and rat platelets and its pharmacological inhibition. Naunyn-Schmiedebergs Arch. Pharmac.296 (1976) 59–65.

    Article  CAS  Google Scholar 

  146. Wood, M. D., and Wyllie, M. G., The inibitory action of imipramine on monoamine transport. Br. J. Pharmac.74 (1981) 890P.

    Google Scholar 

  147. Wood, P. L., Suranyi-Cadotte, B. E., Nair, N. P. V., LaFaille, F., and Schwartz, G., Lack of association of platelet [3H] imipramine binding sites and serotonin uptake in control, depressed and schizophrenic patients. Psychopharmacology (1983) in press.

  148. Yuwiler, A., Ritvo, E., Geller, E., Glousman, R., and Matsuno, D., Uptake and effect of serotonin from platelets of autistic and nonautistic children. J. Autism Childhood Schizophrenia5 (1975) 83–98.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pharmacology and Psychiatry, University of Toronto, 250 College Street, Toronto, Ontario, Canada

    A. Davis

  2. Clinical Research, Boehringer Ingelheim (Canada) Ltd., 977 Century Drive, L7L 5J8, Burlington, Ontario, Canada

    A. Davis

Authors
  1. A. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Acknowledgments. The author's research discussed in this review was supported by the following agencies: The Connaught Foundation, the Hospital for Sick Children, the C. K. Clarke Psychiatric Research Foundation and the Banting Foundation. The research was performed in the Psychopharmacology section, Clarke Institute of Psychiatry, 250 College Street, Toronto, Ontario, Canada. I wish to thank Drs. Dumbrille-Ross, Morris and Tang for helpful discussions and Sheila McCormick for preparation of the manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davis, A. Molecular aspects of the imipramine ‘receptor’. Experientia 40, 782–794 (1984). https://doi.org/10.1007/BF01951960

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01951960

Keywords

Search

Navigation